Author: Admin

Developer

Information Services Group (III) – Adding Real-Time Data Feeds To Its Vendor Compliance And Risk Management Platform

Posted on by Admin


ISG GovernX® Adds Real-Time Data Feeds for Complete Risk Management Solution

 

Newest version of ISG GovernX platform integrates external market data with provider performance metrics and intelligent workflows to quickly address third-party risks

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, said today it is adding real-time data feeds to its market-leading ISG GovernX® vendor compliance and risk management platform, to help clients monitor and respond to risk events as they happen.

GovernX is the industry’s only governance solution that integrates contract information, strategic relationship management and real-time risk monitoring and alerts to pro-actively mitigate business risk. Users can now add a variety of external data feeds to the platform for an unparalleled view of all potential risks, both within their specific supplier ecosystem and from the broader marketplace. Intelligent workflows identify and categorize each risk, alert the appropriate functions, and trigger automated responses, including targeted risk assessments to the suppliers involved.

The new third-party risk management capabilities come as provider ecosystems continue to grow more complex, introducing more risk to the enterprise, and threats against supply-chain integrity become more diverse. In addition to monitoring the operational performance and financial viability of their suppliers, enterprises need to address a range of other internal and external risks, from data security and regulatory issues, to adverse environmental, health and geopolitical events, to social responsibility, diversity and inclusion considerations.

“As companies prioritize digital transformation and increase their reliance on third-party vendors to achieve their goals, it’s no longer enough to simply monitor the supplier landscape and conduct periodic, point-in-time risk assessments,” said Lois Coatney, partner and president, ISG GovernX. “The newest version of our platform proactively monitors a company’s entire landscape and sends real-time alerts on potential threats to the right people, with a clear path for action and resolution.”

Beyond these new risk management capabilities, the ISG GovernX platform allows clients to manage their full portfolio of contracts, ensuring the right controls are in place through the entire contract lifecycle. The platform also manages each supplier’s performance and compliance to obligations, ensuring an accurate and up-to-date profile of each relationship.

“Internal and external intelligence is crucial to a well-managed business, but CIOs and CSOs lose sleep over the many red flags that are missed in the deluge of data that is generated every day,” Coatney said. “Sending information to the right team with a clear record of accountability and follow-through not only helps mitigate risk, it proves to regulators and other stakeholders that a company has evaluated and acted on information in a timely way.

“Combined with our internal supplier performance monitoring, ISG GovernX clients now have a complete inside-out and outside-in view of each supplier’s operational performance, how it is meeting its contractual obligations, and how risks in the supplier’s business and in the broader marketplace can impact overall service and supply chain integrity,” she said.

In 2020, ISG GovernX saw a 90 percent increase in enterprise subscriptions, as clients embrace a more effective way to automate and manage their ever-growing portfolio of software and services contracts and understand potential risks to their supply chain, which have been amplified by the COVID-19 pandemic.

ISG GovernX enables organizations to control costs by managing consumption, validating invoices, optimizing demand, reviewing all new requests against the spending portfolio and controlling value leakage. More than $46 billion of supplier contracts are now managed on GovernX, and there are more than 12,000 active users on the platform.

To learn more about the enhanced risk management capabilities of GovernX, visit this webpage. For an overview of the broader GovernX platform, click here.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

Source: Information Services Group, Inc.

Ocugen (OCGN) – Positive Results Of The Second Interim Analysis Of Phase 3 Study Of COVAXIN

Posted on by Admin


Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization

 

  • Primary efficacy in the second interim analysis demonstrates COVAXIN to be 78% effective after the second dose in preventing COVID-19 in those without prior infection

  • Demonstrates 70% efficacy against asymptomatic COVID-19 infections; indicates potential to significantly reduce virus transmission

  • COVAXIN has been administered to several million people in India and is playing a critical role in combating the pandemic

MALVERN, Pa., April 21, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, shared positive results of the second interim analysis of its Phase 3 study of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate. COVAXIN demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 78% with efficacy against severe COVID-19 disease alone of 100%.

“We continue to be excited by the compelling second interim results of Bharat Biotech’s Phase 3 clinical trial. We believe that COVAXIN can help change the course of this pandemic by preventing severe COVID-19 disease including hospitalizations by 100% as well as significantly limit the spread of asymptomatic COVID-19 infections based on efficacy shown to date. We are dedicated to being a part of the solution to save lives from COVID-19 by bringing COVAXIN to the U.S. market. Based on a traditional vaccine platform that has a long-established safety profile, we believe COVAXIN is an important tool to add to our national arsenal in ending the pandemic,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.

“The safety and efficacy demonstrated by COVAXIN is remarkable because of the prevalence of several variants of the coronavirus circulating at the time of the trial. This vaccine is based on a proven technology platform and the company plans to consider clinical development in special populations such as children,” said Dr. Bruce Forrest, member of the vaccine scientific advisory board of Ocugen.

Second Interim Phase 3 Results as Reported by Bharat Biotech

Bharat Biotech’s Phase 3 clinical trial enrolled 25,800 participants between 18-91 years of age in India, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of the Phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.

The second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19. However, due to the recent surge in cases in India, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% (95%CI: 61-88) against mild, moderate, and severe COVID-19 disease. The trial will be continuing to its pre-planned conclusion.

The efficacy against asymptomatic COVID-19 infection was 70%, based on a subgroup of approximately 8,000 participants who visited the clinical trial site each month for an RT-PCR test.

About COVAXIN

COVAXIN, India’s COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied.

In addition to generating strong immune response against multiple antigens, COVAXIN has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. With published data demonstrating a safety profile superior to available data for several other vaccines, COVAXIN is packaged in multi-dose vials that can be stored at 2-8?C.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

About Bharat Biotech

Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.

Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the world’s largest rabies vaccine manufacturer. To learn more about Bharat Biotech, visit www.bharatbiotech.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data that is the subject of this release), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (FDA) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or emergency use authorization applications may be filed in the United States for COVAXIN; whether and when any such applications may be approved by the FDA; decisions by the FDA impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
CFO and Head of Corp. Dev.
[email protected]

Media Contact:
LaVoieHealthScience
Lisa DeScenza
[email protected]
+1 9783955970

CanAlaska Uranium (CVVUF)(CVV:CA) – Completes Initial Drilling at Waterbury

Posted on by Admin


CanAlaska Completes Initial Drilling at Waterbury

 

First holes contain encouraging fault structures and alteration

Thick graphitic basement package intersected

Vancouver, Canada, April 21, 2021 – CanAlaska Uranium Ltd. (TSX-V: CVV; Frankfurt: DH7N) (“CanAlaska” or the “Company”) has curtailed winter drilling on its 100%-owned Waterbury uranium project. Late permitting and warming weather conditions hampered activities. Only half of the planned winter program was completed. Three drill holes, were completed on the South claim, and none on the East. The focus was to test targets near previously drilled holes which showed significant alteration, uranium values and untested geophysical targets on both the East and South Waterbury claims.

The target on the Waterbury South claim is close to the interpreted location of the regional Rabbit Lake – Collins Bay fault system, host to the Rabbit Lake, Collins Bay and Eagle Point uranium orebodies (Figure 1).

One hole targeted the unconformity one kilometre northeast of drill hole SOD-253 where a resistivity anomaly from a survey completed by CanAlaska highlighted a distinct unconformity breach style anomaly above the basement conductor (Figure 2).  The drillhole located a thick graphitic sequence in the basement and graphitic faults associated with anomalous alteration overprint. The ideal unconformity target related to these structures and alteration remains untested at this stage.

A further two holes tested the unconformity for 150 metres southeast of failed Cameco drill hole SOD-253 and found the basement structures that were the focus of that program.  The historic drillhole been abandoned above the unconformity in a faulted and altered section of Athabasca sandstone. CanAlaska’s new drillholes passed though the sandstone and intersected a thick sequence of graphitic rocks in the basement.  Notably the basement has a zone of strong faulting, and wide sections of very intense alteration consisting of clay, secondary hematization, and dravite, which together are prime signatures of fluid flow associated with uranium mineralizing events in the Athabasca region.

Core samples were collected and sent to the Saskatchewan Research Council (SRC) for geochemical analysis. Samples for clay analysis are currently being processed.

President Peter Dasler commented: “the drill team has confirmed the geophysical interpretation of strongly altered basement and sandstone with underlying reactive graphitic sediments. These are a very encouraging features for us to focus our next drill program at Waterbury South.  It is unfortunate that timing and weather did not allow further holes this season, however we have significantly upgraded the current target at Waterbury south, and look forward to getting another chance for discovery.”

About CanAlaska Uranium

 CanAlaska Uranium Ltd. (TSX-V: CVV;Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres), in Canada’s Athabasca Basin and Wollaston area – the “Saudi Arabia of Uranium.”  CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds.

For further information visit www.canalaska.com.

The qualified technical person for this news release is Dr Karl Schimann, P. Geo, CanAlaska director and VP Exploration.

On behalf of the Board of Directors

“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President & CEO
CanAlaska Uranium Ltd.

Contacts:

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: [email protected]

Cory Belyk, COO
Tel: +1.604.688.3211 x 138
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Energy Fuels (UUUU)(EFR:CA) – Energy Fuels and Hyperion Sign MOU for the Supply of Monazite to Produce Rare Earth Products

Posted on by Admin

 

 


Energy Fuels and Hyperion Sign MOU for the Supply of Monazite to Produce Rare Earth Products

 

A Further Step in the Development of a Fully Integrated U.S. Rare Earth Element Supply Chain

  • Energy Fuels and Hyperion have signed a memorandum of understanding to evaluate the potential supply of monazite sands from the Titan Project in Tennessee to Energy Fuels’ White Mesa Mill in Utah for the production of rare earth products.

  • Monazite is a very valuable rare earth-bearing mineral, planned to be produced at the Titan Project as a component of its heavy mineral sand concentrate product.

  • The MOU highlights the potential importance of Hyperion’s Titan Project, as Energy Fuels advances its initiatives to establish a fully integrated, low-cost U.S rare earth element supply chain.

  • Energy Fuels and Hyperion will also evaluate a potential arrangement to collaborate in the development of an integrated U.S. rare earth supply chain.

LAKEWOOD, Colo., April 21, 2021 /CNW/ – Energy Fuels Inc. (“Energy Fuels”) (NYSE: UUUU) (TSX: EFR) and Hyperion Metals Limited (“Hyperion”) (ASX: HYM) are pleased to announce the execution of a non-binding memorandum of understanding (“MOU“) for the supply of natural monazite sands (“Monazite“) from Hyperion’s Titan Project in Tennessee (the “Titan Project“). Energy Fuels plans to produce mixed rare earth element (“REE“) products from processing the Monazite at its White Mesa Mill in Utah.

The parties have also agreed to evaluate a potential teaming, joint venture, equity investment or other arrangement under which Hyperion would collaborate with Energy Fuels, and potentially other parties, in advancing Energy Fuels’ current initiative to establish a fully integrated, “mine to market” U.S. rare earth supply chain for the electric vehicle and renewable energy sectors, as well as other specialty uses.

The collaboration between Energy Fuels and Hyperion will initially focus on the potential commercial supply of Monazite from Hyperion’s Titan Project to Energy Fuels’ White Mesa Mill. Under the MOU, the parties have agreed to negotiate a definitive sales agreement for this supply of Monazite. In addition, subject to Hyperion supplying Energy Fuels with a sufficient quantity of Monazite from the Titan Project within a reasonable period of time, Hyperion and Energy Fuels will evaluate entering into a joint venture or other similar arrangement whereby Hyperion would participate with Energy Fuels, and potentially other parties, in the continuing development and operation of an integrated, low-cost and sustainable independent U.S. rare earth supply chain, under which Monazite would be supplied from The Chemours Company (NYSE: CC) (“Chemours“) U.S. projects, the Titan Project, and potentially other U.S and international mines, with the Monazite to be processed and separated into value-added rare earth products at Energy Fuels’ White Mesa Mill. This could potentially also result in the development of rare earth metal production capabilities.

Hyperion’s Titan Project covers a large area of heavy mineral sands properties in Tennessee prospective for titanium, zircon, Monazite and other valuable minerals such as high-grade silica sand and other refractory minerals. The Titan Project is in an area which saw significant historic exploration from 1960 – 1990 by DuPont, BHP and others, strategically located in the southeast of the U.S., close to significant manufacturing capacity, providing what Hyperion believes to be a significant logistical advantage over current U.S. supplies of imported titanium feedstock.

Hyperion is nearing completion of a three-phase drilling and bulk sampling test work program at the Titan Project. Results to date have successfully confirmed the high grade and significant thickness of mineralization over approximately a 3.6 km strike length. Assays from the drill programs to date have returned thick zones of high-grade Total Heavy Mineral (“THM“) near surface, with highlights including:

  • 47.2m @ 3.69% THM including 10.7m @ 8.09% THM and 10.7m @ 5.47% THM
  • 36.6m @ 3.37% THM including 12.2m @ 7.65% THM
  • 35.1m @ 3.04% THM including 10.7m @ 8.16% THM
  • 41.1m @ 2.14% THM including 9.1m @ 5.55 THM
  • 33.5m @ 2.21% THM including 12.2m @ 5.64% THM

Hyperion’s bulk sampling test work for flow-sheet development is nearing completion, and is evaluating the production of a number of mineral products, including:

  • Titanium minerals – used to produce titanium metal and for the production of paint and pigments;
  • Monazite – used for the production of rare earth products;
  • Zircon – used for the ceramic and foundry markets; and
  • High quality silica – used in float glass, solar panel glass and pharmaceutical grade glass.

A 70-hole Phase 3 drill program is nearing completion, and together with the bulk sample program will form the basis for Hyperion’s initial mineral resource estimate expected to be delivered in Q2 2021. For more information about the Titan Project go to:  www.hyperionmetals.us

Energy Fuels and Neo Performance Materials Inc. (TSX: NEO) (“Neo“) recently announced the joint launch of a U.S.-European REE supply chain involving Energy Fuels, Neo and Chemours. Under this emerging initiative, Energy Fuels is currently purchasing 2,500 tons of Monazite per year from the Chemours Company’s Georgia (USA) heavy mineral sand operations. Energy Fuels is currently processing this Monazite at its White Mesa Mill in Utah into a clean, mixed REE carbonate, as well as recovering the contained uranium. Energy Fuels is selling this intermediate REE product to Neo’s REE separations facility in Sillamae, Estonia for the production of commercial value-added REE products, supplying U.S. and European markets.

In addition to producing mixed REE carbonate, Energy Fuels is also evaluating the potential to develop U.S. separation, metals, alloys, and other downstream REE capabilities at the White Mesa Mill, or nearby, thereby fully integrating a U.S. rare earth supply chain in the coming years. Energy Fuels is seeking to increase its supply of Monazite feed to approximately 15,000 tons per year (or greater) for this initiative. Subject to completion of permitting, development and commencement of operations, the Titan Project is expected to be a potential future source of Monazite to supplement Chemours’ supply of Monazite to Energy Fuels.

The MOU highlights the importance of Hyperion’s Titan Project as a potentially important source of high value American rare earth minerals, expected to play an integral role in rebuilding sustainable, robust and resilient transportation, energy and defense sectors, and the desire of Energy Fuels to build diversified and significant Monazite feedstocks from various sources.

Energy Fuels’ President and Chief Executive Officer, Mr. Mark Chalmers, said: “Energy Fuels, along with Chemours and Neo, are creating a new U.S.-Europe rare earth supply chain. For this initiative to achieve its full potential, we are actively seeking new, ethically-produced sources of Monazite, with sources from the U.S. being our first priority. Therefore, we are excited to work with Hyperion to secure additional sources of Monazite for processing at the White Mesa Mill. Through their association with Piedmont Lithium’s project in North Carolina, members of the Hyperion team have demonstrated to us that they have the know-how and resources to bring U.S. critical mineral projects into production. We look forward to working with the Hyperion team and potentially seeing our relationship grow through their participation in a fully-integrated, low cost U.S. rare earth supply chain in the future. We are particularly excited about the prospect of sourcing U.S. mined Monazite, which together with our current supplies from Chemours’ Georgia operations and the unique capabilities of the White Mesa Mill, demonstrates to us that a world-competitive and world-scale, fully integrated U.S. rare earth supply chain is becoming a reality.”

Hyperion’s Managing Director, Mr. Anastasios Arima, said: “We are excited to progress the potential supply to Energy Fuels of American Monazite for its rare earths supply chain right here in the USA, bringing back sustainable American industry and skilled jobs for generations. The import dependence of the U.S. for key critical minerals, including rare earths and titanium, presents a huge threat to the security of key domestic industries, including defense, space, aerospace, renewables and electric vehicles. Our collaboration with Energy Fuels highlights the importance of Hyperion’s Titan Project in the U.S. as a leader in American sourced critical minerals through its plans to produce zero carbon titanium metals, delivering a clean energy future through the supply of rare earth elements for electric vehicles and the renewable power sectors.”

This announcement has been authorized for release by Hyperion’s Managing Director.

About Energy Fuels: Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and is in the process of ramping-up to commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR“) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate and uranium from Monazite. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com.

About Hyperion: Hyperion Metals’ mission is to be the leading developer of zero carbon, sustainable, critical material supply chains for advanced American industries including space, aerospace, electric vehicles and 3D printing. The Company holds a 100% interest in the Titan Project, covering nearly 4,000 acres of prospective titanium, rare earth minerals, high grade silica sand and zircon mineral sands properties in Tennessee, USA, as well as an option to secure the exclusive license to produce low carbon titanium metal using the breakthrough HAMR technology, invented by Dr. Z. Zak Fang and his team at the University of Utah with government funding from ARPA-E. The primary trading market for Hyperion’s common shares is the Australian Stock Exchange under the trading symbol “HYM.” Hyperion’s website is www.hyperionmetals.us.

Cautionary Statements Regarding Forward Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws in the United States, Canada, and Australia. Forward-looking information may relate to future events or future performance of Energy Fuels or Hyperion. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ or Hyperion’s objectives and goals, as well as statements with respect to their beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation that the Titan Project will be permitted and developed into a commercial producing mine; any expectation that the Titan Project will provide a significant logistical advantage over current U.S. supplies of imported titanium feedstock; any expectation that future exploration or bulk sample results at the Titan Project will meet expectations; any expectation that a JORC Code report will be prepared for the Titan Project and that it will confirm current exploration or bulk sampling results or otherwise meet expectations; any expectation that the Titan Project will contain Monazite in a commercial form or that the Titan Project will be capable of producing satisfactory amounts of Monazite per year; any estimation of the mine life of the Titan Project or when it may commence production of Monazite, if at all; any expectation that the White Mesa Mill will be successful in producing REE carbonate on a commercial basis; any expectation that Neo will be successful in separating the White Mesa Mill’s REE carbonate on a commercial basis; any expectation that Energy Fuels will be successful in increasing its supplies of Monazite, developing U.S. separation, metals or metal/alloy capabilities at the White Mesa Mill or nearby, or otherwise fully integrating a low cost U.S REE supply chain in the future; any expectation with respect to the quantities of Monazite to be acquired by Energy Fuels; any expectation with regard to the cost of producing and separating REE carbonate; and any expectation that Energy Fuels and Hyperion will be successful in completing definitive agreements and hence proceeding with their collaborative efforts . Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: permitting and developing the Titan Project; exploration results not meeting expectations on the Titan Project; commodity prices; the Titan Project never going into production; legal challenges and injunctions; processing difficulties and upsets; available supplies of Monazite; the ability of the White Mesa Mill to produce REE carbonate to meet commercial specifications on a commercial scale at acceptable costs; the ability of Neo to separate REE carbonate to meet commercial specifications on a commercial scale at acceptable costs; market factors, including future demand for REEs; and the ability of Energy Fuels and Hyperion to finalize definitive agreements. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels and Hyperion disclaim, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels and Hyperion assume no obligation to update the information in this communication, except as otherwise required by law.

Competent Persons Statement

The information in this announcement that relates to the Titan Project Exploration Results is extracted from Hyperion’s ASX Announcements dated 10 March 2021 and 7 January 2021 (“Original ASX Announcements”) which are available to view at Hyperion’s website at www.hyperionmetals.us. Hyperion confirms that a) it is not aware of any new information or data that materially affects the information included in the Original ASX Announcements; b) all material assumptions included in the Original ASX Announcements continue to apply and have not materially changed; and c) the form and context in which the relevant Competent Persons’ findings are presented in this report have not been materially changed from the Original ASX Announcements.

SOURCE Energy Fuels Inc.

For further information: Energy Fuels Inc., Curtis Moore – VP – Marketing & Corporate Development, (303) 974-2140 or Toll free: (888) 864-2125, [email protected], www.energyfuels.com; Hyperion Metals Limited, Anastasios (Taso) Arima – Managing Director, +1 347 899 1522, [email protected], www.hyperionmetals.us; Hyperion Metals Limited, Dominic Allen – Corporate Development, +61 468 544 888, [email protected], www.hyperionmetals.us

Earth Day Stocks to Review

Posted on by Admin

 


Earth Friendly Stocks for Earth Day (and beyond)

 

The first Earth Day, back in 1970, was the idea of Senator Gaylord Nelson as a way to force environmental issues into the national discussion. At the time, there was no EPA, no Clean Air Act, no Clean Water Act, and no smog or efficiency standards – the average car averaged 11.9 mpg on leaded gasoline.

Since that first Earth Day on April 22, 1970, each that has followed has been an occasion to celebrate past successes and recognize how much more can be done. From the perspective of an inhabitant of this planet, the progress benefits us now and preserves sustainability for the future; from purely an investor’s standpoint, cleaner environmental initiatives lead to the kind of change in spending that provides opportunity. The year 2021 is ushering in these opportunities with a number of objectives that will force transition in many businesses. High on the list in the U.S. is the re-signing of the Paris Agreement earlier this year. Additionally, President Biden has pledged that the country will work to slash America’s greenhouse gas emissions at least in half by 2030, with longer-term efforts to achieve a 100% clean energy economy and reach net-zero emissions no later than 2050. The U.S. president is hosting a virtual summit of 40 world leaders to discuss climate initiatives this week. During the summit, Biden is expected to ask for new commitments from the world’s biggest carbon emitters.

Earlier this year, Biden had proposed an infrastructure initiative, in which he expects to spend $2 trillion over eight years for infrastructure projects to curb the country’s greenhouse gas emissions. Portions of this corporate tax-funded spending will be used for clean-energy measures, including electric vehicle funding, research, and development, the addition of charging stations and retrofitting buildings and residences.

 

Five Earth-Friendly Stocks to Read Up On

An even greener red, white, and blue will make winners out of companies that were barely getting noticed a few of years ago. Environmental regulation and changing business attitudes focusing more on ESG will impact sectors such as manufacturing, fuel generation, metals and mining, utilities, and others. Below are five Earth-friendly stocks that could be worth checking in on.

 

GEVO Inc. (GEVO) is a renewable chemicals and biofuels company that develops and brings to market alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks.

The “low carbon” fuel company has developed a breakthrough process that converts a high-octane fuel called isobutanol into clean, renewable diesel. The green diesel can also be made from fusel oils, a mixture of several alcohols produced as a by-product of fermentation.

 

Capstone
Turbine Corp. (CPST,
CS:CA) is a leading global producer of highly efficient, low emission, microturbine energy systems. Their microturbines serve multiple vertical markets throughout the world; they include natural resources, energy efficiency, renewable energy, critical power supply, transportation, and microgrids.

 

Comstock
Mining Inc. (LODE)  is an emerging leader in the sustainable extraction, valorization, and production of innovation-based, clean, renewable natural resources. Their focus is on high-value, cash-generating, strategic materials that are essential to meeting the rapidly increasing global demand for clean energy, carbon neutrality, and natural products.

 

Energy
Fuels (UUUU,
EFR:CA) is a leading U.S.-based uranium mining company supplying U308 to major utilities operating in the nuclear realm. The company also produces vanadium from certain projects as called for by market demand. Energy fuels expects to begin commercial production of rare earth element (REE) carbonate in 2021.

 

enCore
Energy (ENCUF,
TSX:V) is a uranium explorer and developer focused on growing its portfolio of ISR (in situ recovery) and conventional assets in the U.S. The experienced team of uranium experts have advanced large domestic growth
projects and successful sale of those projects.

 

Take-Away

As we recognize our 51st Earth Day it’s good to remember that at that time there was very little regard for the impact of industry on the planet. While some countries now have a better record than others, and more service-related industries are naturally more green, the strides we’ve made over five decades have yielded measurable results. As the global push toward a “greener” environment accelerates, there will be winners; whether an investor considers themselves to be an “impact investor” or an investor that is following trends, Earth-friendly investments offer tremendous potential.

 

Suggested Videos:

 

enCore Energy C-Suite Interview

Capstone Turbine Virtual Road Show Replay



Comstock Mining Virtual Road Show Replay

Energy Fuels C-Suite Interview

 

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Energy Fuels (UUUU)(EFR:CA) – Energy Fuels and Hyperion Sign MOU for the Supply of Monazite to Produce Rare Earth Products

Posted on by Admin

 

 


Energy Fuels and Hyperion Sign MOU for the Supply of Monazite to Produce Rare Earth Products

 

A Further Step in the Development of a Fully Integrated U.S. Rare Earth Element Supply Chain

  • Energy Fuels and Hyperion have signed a memorandum of understanding to evaluate the potential supply of monazite sands from the Titan Project in Tennessee to Energy Fuels’ White Mesa Mill in Utah for the production of rare earth products.

  • Monazite is a very valuable rare earth-bearing mineral, planned to be produced at the Titan Project as a component of its heavy mineral sand concentrate product.

  • The MOU highlights the potential importance of Hyperion’s Titan Project, as Energy Fuels advances its initiatives to establish a fully integrated, low-cost U.S rare earth element supply chain.

  • Energy Fuels and Hyperion will also evaluate a potential arrangement to collaborate in the development of an integrated U.S. rare earth supply chain.

LAKEWOOD, Colo., April 21, 2021 /CNW/ – Energy Fuels Inc. (“Energy Fuels”) (NYSE: UUUU) (TSX: EFR) and Hyperion Metals Limited (“Hyperion”) (ASX: HYM) are pleased to announce the execution of a non-binding memorandum of understanding (“MOU“) for the supply of natural monazite sands (“Monazite“) from Hyperion’s Titan Project in Tennessee (the “Titan Project“). Energy Fuels plans to produce mixed rare earth element (“REE“) products from processing the Monazite at its White Mesa Mill in Utah.

The parties have also agreed to evaluate a potential teaming, joint venture, equity investment or other arrangement under which Hyperion would collaborate with Energy Fuels, and potentially other parties, in advancing Energy Fuels’ current initiative to establish a fully integrated, “mine to market” U.S. rare earth supply chain for the electric vehicle and renewable energy sectors, as well as other specialty uses.

The collaboration between Energy Fuels and Hyperion will initially focus on the potential commercial supply of Monazite from Hyperion’s Titan Project to Energy Fuels’ White Mesa Mill. Under the MOU, the parties have agreed to negotiate a definitive sales agreement for this supply of Monazite. In addition, subject to Hyperion supplying Energy Fuels with a sufficient quantity of Monazite from the Titan Project within a reasonable period of time, Hyperion and Energy Fuels will evaluate entering into a joint venture or other similar arrangement whereby Hyperion would participate with Energy Fuels, and potentially other parties, in the continuing development and operation of an integrated, low-cost and sustainable independent U.S. rare earth supply chain, under which Monazite would be supplied from The Chemours Company (NYSE: CC) (“Chemours“) U.S. projects, the Titan Project, and potentially other U.S and international mines, with the Monazite to be processed and separated into value-added rare earth products at Energy Fuels’ White Mesa Mill. This could potentially also result in the development of rare earth metal production capabilities.

Hyperion’s Titan Project covers a large area of heavy mineral sands properties in Tennessee prospective for titanium, zircon, Monazite and other valuable minerals such as high-grade silica sand and other refractory minerals. The Titan Project is in an area which saw significant historic exploration from 1960 – 1990 by DuPont, BHP and others, strategically located in the southeast of the U.S., close to significant manufacturing capacity, providing what Hyperion believes to be a significant logistical advantage over current U.S. supplies of imported titanium feedstock.

Hyperion is nearing completion of a three-phase drilling and bulk sampling test work program at the Titan Project. Results to date have successfully confirmed the high grade and significant thickness of mineralization over approximately a 3.6 km strike length. Assays from the drill programs to date have returned thick zones of high-grade Total Heavy Mineral (“THM“) near surface, with highlights including:

  • 47.2m @ 3.69% THM including 10.7m @ 8.09% THM and 10.7m @ 5.47% THM
  • 36.6m @ 3.37% THM including 12.2m @ 7.65% THM
  • 35.1m @ 3.04% THM including 10.7m @ 8.16% THM
  • 41.1m @ 2.14% THM including 9.1m @ 5.55 THM
  • 33.5m @ 2.21% THM including 12.2m @ 5.64% THM

Hyperion’s bulk sampling test work for flow-sheet development is nearing completion, and is evaluating the production of a number of mineral products, including:

  • Titanium minerals – used to produce titanium metal and for the production of paint and pigments;
  • Monazite – used for the production of rare earth products;
  • Zircon – used for the ceramic and foundry markets; and
  • High quality silica – used in float glass, solar panel glass and pharmaceutical grade glass.

A 70-hole Phase 3 drill program is nearing completion, and together with the bulk sample program will form the basis for Hyperion’s initial mineral resource estimate expected to be delivered in Q2 2021. For more information about the Titan Project go to:  www.hyperionmetals.us

Energy Fuels and Neo Performance Materials Inc. (TSX: NEO) (“Neo“) recently announced the joint launch of a U.S.-European REE supply chain involving Energy Fuels, Neo and Chemours. Under this emerging initiative, Energy Fuels is currently purchasing 2,500 tons of Monazite per year from the Chemours Company’s Georgia (USA) heavy mineral sand operations. Energy Fuels is currently processing this Monazite at its White Mesa Mill in Utah into a clean, mixed REE carbonate, as well as recovering the contained uranium. Energy Fuels is selling this intermediate REE product to Neo’s REE separations facility in Sillamae, Estonia for the production of commercial value-added REE products, supplying U.S. and European markets.

In addition to producing mixed REE carbonate, Energy Fuels is also evaluating the potential to develop U.S. separation, metals, alloys, and other downstream REE capabilities at the White Mesa Mill, or nearby, thereby fully integrating a U.S. rare earth supply chain in the coming years. Energy Fuels is seeking to increase its supply of Monazite feed to approximately 15,000 tons per year (or greater) for this initiative. Subject to completion of permitting, development and commencement of operations, the Titan Project is expected to be a potential future source of Monazite to supplement Chemours’ supply of Monazite to Energy Fuels.

The MOU highlights the importance of Hyperion’s Titan Project as a potentially important source of high value American rare earth minerals, expected to play an integral role in rebuilding sustainable, robust and resilient transportation, energy and defense sectors, and the desire of Energy Fuels to build diversified and significant Monazite feedstocks from various sources.

Energy Fuels’ President and Chief Executive Officer, Mr. Mark Chalmers, said: “Energy Fuels, along with Chemours and Neo, are creating a new U.S.-Europe rare earth supply chain. For this initiative to achieve its full potential, we are actively seeking new, ethically-produced sources of Monazite, with sources from the U.S. being our first priority. Therefore, we are excited to work with Hyperion to secure additional sources of Monazite for processing at the White Mesa Mill. Through their association with Piedmont Lithium’s project in North Carolina, members of the Hyperion team have demonstrated to us that they have the know-how and resources to bring U.S. critical mineral projects into production. We look forward to working with the Hyperion team and potentially seeing our relationship grow through their participation in a fully-integrated, low cost U.S. rare earth supply chain in the future. We are particularly excited about the prospect of sourcing U.S. mined Monazite, which together with our current supplies from Chemours’ Georgia operations and the unique capabilities of the White Mesa Mill, demonstrates to us that a world-competitive and world-scale, fully integrated U.S. rare earth supply chain is becoming a reality.”

Hyperion’s Managing Director, Mr. Anastasios Arima, said: “We are excited to progress the potential supply to Energy Fuels of American Monazite for its rare earths supply chain right here in the USA, bringing back sustainable American industry and skilled jobs for generations. The import dependence of the U.S. for key critical minerals, including rare earths and titanium, presents a huge threat to the security of key domestic industries, including defense, space, aerospace, renewables and electric vehicles. Our collaboration with Energy Fuels highlights the importance of Hyperion’s Titan Project in the U.S. as a leader in American sourced critical minerals through its plans to produce zero carbon titanium metals, delivering a clean energy future through the supply of rare earth elements for electric vehicles and the renewable power sectors.”

This announcement has been authorized for release by Hyperion’s Managing Director.

About Energy Fuels: Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The Company also produces vanadium from certain of its projects, as market conditions warrant, and is in the process of ramping-up to commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR“) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate and uranium from Monazite. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com.

About Hyperion: Hyperion Metals’ mission is to be the leading developer of zero carbon, sustainable, critical material supply chains for advanced American industries including space, aerospace, electric vehicles and 3D printing. The Company holds a 100% interest in the Titan Project, covering nearly 4,000 acres of prospective titanium, rare earth minerals, high grade silica sand and zircon mineral sands properties in Tennessee, USA, as well as an option to secure the exclusive license to produce low carbon titanium metal using the breakthrough HAMR technology, invented by Dr. Z. Zak Fang and his team at the University of Utah with government funding from ARPA-E. The primary trading market for Hyperion’s common shares is the Australian Stock Exchange under the trading symbol “HYM.” Hyperion’s website is www.hyperionmetals.us.

Cautionary Statements Regarding Forward Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws in the United States, Canada, and Australia. Forward-looking information may relate to future events or future performance of Energy Fuels or Hyperion. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ or Hyperion’s objectives and goals, as well as statements with respect to their beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation that the Titan Project will be permitted and developed into a commercial producing mine; any expectation that the Titan Project will provide a significant logistical advantage over current U.S. supplies of imported titanium feedstock; any expectation that future exploration or bulk sample results at the Titan Project will meet expectations; any expectation that a JORC Code report will be prepared for the Titan Project and that it will confirm current exploration or bulk sampling results or otherwise meet expectations; any expectation that the Titan Project will contain Monazite in a commercial form or that the Titan Project will be capable of producing satisfactory amounts of Monazite per year; any estimation of the mine life of the Titan Project or when it may commence production of Monazite, if at all; any expectation that the White Mesa Mill will be successful in producing REE carbonate on a commercial basis; any expectation that Neo will be successful in separating the White Mesa Mill’s REE carbonate on a commercial basis; any expectation that Energy Fuels will be successful in increasing its supplies of Monazite, developing U.S. separation, metals or metal/alloy capabilities at the White Mesa Mill or nearby, or otherwise fully integrating a low cost U.S REE supply chain in the future; any expectation with respect to the quantities of Monazite to be acquired by Energy Fuels; any expectation with regard to the cost of producing and separating REE carbonate; and any expectation that Energy Fuels and Hyperion will be successful in completing definitive agreements and hence proceeding with their collaborative efforts . Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: permitting and developing the Titan Project; exploration results not meeting expectations on the Titan Project; commodity prices; the Titan Project never going into production; legal challenges and injunctions; processing difficulties and upsets; available supplies of Monazite; the ability of the White Mesa Mill to produce REE carbonate to meet commercial specifications on a commercial scale at acceptable costs; the ability of Neo to separate REE carbonate to meet commercial specifications on a commercial scale at acceptable costs; market factors, including future demand for REEs; and the ability of Energy Fuels and Hyperion to finalize definitive agreements. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels and Hyperion disclaim, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels and Hyperion assume no obligation to update the information in this communication, except as otherwise required by law.

Competent Persons Statement

The information in this announcement that relates to the Titan Project Exploration Results is extracted from Hyperion’s ASX Announcements dated 10 March 2021 and 7 January 2021 (“Original ASX Announcements”) which are available to view at Hyperion’s website at www.hyperionmetals.us. Hyperion confirms that a) it is not aware of any new information or data that materially affects the information included in the Original ASX Announcements; b) all material assumptions included in the Original ASX Announcements continue to apply and have not materially changed; and c) the form and context in which the relevant Competent Persons’ findings are presented in this report have not been materially changed from the Original ASX Announcements.

SOURCE Energy Fuels Inc.

For further information: Energy Fuels Inc., Curtis Moore – VP – Marketing & Corporate Development, (303) 974-2140 or Toll free: (888) 864-2125, [email protected], www.energyfuels.com; Hyperion Metals Limited, Anastasios (Taso) Arima – Managing Director, +1 347 899 1522, [email protected], www.hyperionmetals.us; Hyperion Metals Limited, Dominic Allen – Corporate Development, +61 468 544 888, [email protected], www.hyperionmetals.us

Release – CanAlaska Uranium (CVVUF)(CVV:CA) – Completes Initial Drilling at Waterbury

Posted on by Admin


CanAlaska Completes Initial Drilling at Waterbury

 

First holes contain encouraging fault structures and alteration

Thick graphitic basement package intersected

Vancouver, Canada, April 21, 2021 – CanAlaska Uranium Ltd. (TSX-V: CVV; Frankfurt: DH7N) (“CanAlaska” or the “Company”) has curtailed winter drilling on its 100%-owned Waterbury uranium project. Late permitting and warming weather conditions hampered activities. Only half of the planned winter program was completed. Three drill holes, were completed on the South claim, and none on the East. The focus was to test targets near previously drilled holes which showed significant alteration, uranium values and untested geophysical targets on both the East and South Waterbury claims.

The target on the Waterbury South claim is close to the interpreted location of the regional Rabbit Lake – Collins Bay fault system, host to the Rabbit Lake, Collins Bay and Eagle Point uranium orebodies (Figure 1).

One hole targeted the unconformity one kilometre northeast of drill hole SOD-253 where a resistivity anomaly from a survey completed by CanAlaska highlighted a distinct unconformity breach style anomaly above the basement conductor (Figure 2).  The drillhole located a thick graphitic sequence in the basement and graphitic faults associated with anomalous alteration overprint. The ideal unconformity target related to these structures and alteration remains untested at this stage.

A further two holes tested the unconformity for 150 metres southeast of failed Cameco drill hole SOD-253 and found the basement structures that were the focus of that program.  The historic drillhole been abandoned above the unconformity in a faulted and altered section of Athabasca sandstone. CanAlaska’s new drillholes passed though the sandstone and intersected a thick sequence of graphitic rocks in the basement.  Notably the basement has a zone of strong faulting, and wide sections of very intense alteration consisting of clay, secondary hematization, and dravite, which together are prime signatures of fluid flow associated with uranium mineralizing events in the Athabasca region.

Core samples were collected and sent to the Saskatchewan Research Council (SRC) for geochemical analysis. Samples for clay analysis are currently being processed.

President Peter Dasler commented: “the drill team has confirmed the geophysical interpretation of strongly altered basement and sandstone with underlying reactive graphitic sediments. These are a very encouraging features for us to focus our next drill program at Waterbury South.  It is unfortunate that timing and weather did not allow further holes this season, however we have significantly upgraded the current target at Waterbury south, and look forward to getting another chance for discovery.”

About CanAlaska Uranium

 CanAlaska Uranium Ltd. (TSX-V: CVV;Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres), in Canada’s Athabasca Basin and Wollaston area – the “Saudi Arabia of Uranium.”  CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds.

For further information visit www.canalaska.com.

The qualified technical person for this news release is Dr Karl Schimann, P. Geo, CanAlaska director and VP Exploration.

On behalf of the Board of Directors

“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President & CEO
CanAlaska Uranium Ltd.

Contacts:

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: [email protected]

Cory Belyk, COO
Tel: +1.604.688.3211 x 138
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Release – Ocugen (OCGN) – Positive Results Of The Second Interim Analysis Of Phase 3 Study Of COVAXIN

Posted on by Admin


Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization

 

  • Primary efficacy in the second interim analysis demonstrates COVAXIN to be 78% effective after the second dose in preventing COVID-19 in those without prior infection

  • Demonstrates 70% efficacy against asymptomatic COVID-19 infections; indicates potential to significantly reduce virus transmission

  • COVAXIN has been administered to several million people in India and is playing a critical role in combating the pandemic

MALVERN, Pa., April 21, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, shared positive results of the second interim analysis of its Phase 3 study of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate. COVAXIN demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 78% with efficacy against severe COVID-19 disease alone of 100%.

“We continue to be excited by the compelling second interim results of Bharat Biotech’s Phase 3 clinical trial. We believe that COVAXIN can help change the course of this pandemic by preventing severe COVID-19 disease including hospitalizations by 100% as well as significantly limit the spread of asymptomatic COVID-19 infections based on efficacy shown to date. We are dedicated to being a part of the solution to save lives from COVID-19 by bringing COVAXIN to the U.S. market. Based on a traditional vaccine platform that has a long-established safety profile, we believe COVAXIN is an important tool to add to our national arsenal in ending the pandemic,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.

“The safety and efficacy demonstrated by COVAXIN is remarkable because of the prevalence of several variants of the coronavirus circulating at the time of the trial. This vaccine is based on a proven technology platform and the company plans to consider clinical development in special populations such as children,” said Dr. Bruce Forrest, member of the vaccine scientific advisory board of Ocugen.

Second Interim Phase 3 Results as Reported by Bharat Biotech

Bharat Biotech’s Phase 3 clinical trial enrolled 25,800 participants between 18-91 years of age in India, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of the Phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.

The second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19. However, due to the recent surge in cases in India, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% (95%CI: 61-88) against mild, moderate, and severe COVID-19 disease. The trial will be continuing to its pre-planned conclusion.

The efficacy against asymptomatic COVID-19 infection was 70%, based on a subgroup of approximately 8,000 participants who visited the clinical trial site each month for an RT-PCR test.

About COVAXIN

COVAXIN, India’s COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied.

In addition to generating strong immune response against multiple antigens, COVAXIN has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. With published data demonstrating a safety profile superior to available data for several other vaccines, COVAXIN is packaged in multi-dose vials that can be stored at 2-8?C.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

About Bharat Biotech

Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.

Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the world’s largest rabies vaccine manufacturer. To learn more about Bharat Biotech, visit www.bharatbiotech.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data that is the subject of this release), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (FDA) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or emergency use authorization applications may be filed in the United States for COVAXIN; whether and when any such applications may be approved by the FDA; decisions by the FDA impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
CFO and Head of Corp. Dev.
[email protected]

Media Contact:
LaVoieHealthScience
Lisa DeScenza
[email protected]
+1 9783955970

Release – Information Services Group (III) – Adding Real-Time Data Feeds To Its Vendor Compliance And Risk Management Platform

Posted on by Admin


ISG GovernX® Adds Real-Time Data Feeds for Complete Risk Management Solution

 

Newest version of ISG GovernX platform integrates external market data with provider performance metrics and intelligent workflows to quickly address third-party risks

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, said today it is adding real-time data feeds to its market-leading ISG GovernX® vendor compliance and risk management platform, to help clients monitor and respond to risk events as they happen.

GovernX is the industry’s only governance solution that integrates contract information, strategic relationship management and real-time risk monitoring and alerts to pro-actively mitigate business risk. Users can now add a variety of external data feeds to the platform for an unparalleled view of all potential risks, both within their specific supplier ecosystem and from the broader marketplace. Intelligent workflows identify and categorize each risk, alert the appropriate functions, and trigger automated responses, including targeted risk assessments to the suppliers involved.

The new third-party risk management capabilities come as provider ecosystems continue to grow more complex, introducing more risk to the enterprise, and threats against supply-chain integrity become more diverse. In addition to monitoring the operational performance and financial viability of their suppliers, enterprises need to address a range of other internal and external risks, from data security and regulatory issues, to adverse environmental, health and geopolitical events, to social responsibility, diversity and inclusion considerations.

“As companies prioritize digital transformation and increase their reliance on third-party vendors to achieve their goals, it’s no longer enough to simply monitor the supplier landscape and conduct periodic, point-in-time risk assessments,” said Lois Coatney, partner and president, ISG GovernX. “The newest version of our platform proactively monitors a company’s entire landscape and sends real-time alerts on potential threats to the right people, with a clear path for action and resolution.”

Beyond these new risk management capabilities, the ISG GovernX platform allows clients to manage their full portfolio of contracts, ensuring the right controls are in place through the entire contract lifecycle. The platform also manages each supplier’s performance and compliance to obligations, ensuring an accurate and up-to-date profile of each relationship.

“Internal and external intelligence is crucial to a well-managed business, but CIOs and CSOs lose sleep over the many red flags that are missed in the deluge of data that is generated every day,” Coatney said. “Sending information to the right team with a clear record of accountability and follow-through not only helps mitigate risk, it proves to regulators and other stakeholders that a company has evaluated and acted on information in a timely way.

“Combined with our internal supplier performance monitoring, ISG GovernX clients now have a complete inside-out and outside-in view of each supplier’s operational performance, how it is meeting its contractual obligations, and how risks in the supplier’s business and in the broader marketplace can impact overall service and supply chain integrity,” she said.

In 2020, ISG GovernX saw a 90 percent increase in enterprise subscriptions, as clients embrace a more effective way to automate and manage their ever-growing portfolio of software and services contracts and understand potential risks to their supply chain, which have been amplified by the COVID-19 pandemic.

ISG GovernX enables organizations to control costs by managing consumption, validating invoices, optimizing demand, reviewing all new requests against the spending portfolio and controlling value leakage. More than $46 billion of supplier contracts are now managed on GovernX, and there are more than 12,000 active users on the platform.

To learn more about the enhanced risk management capabilities of GovernX, visit this webpage. For an overview of the broader GovernX platform, click here.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.

Source: Information Services Group, Inc.

Release – Gevo (GEVO) – To Report First Quarter 2021 Financial Results on May 13 2021

Posted on by Admin


Gevo to Report First Quarter 2021 Financial Results on May 13, 2021

 

ENGLEWOOD, Colorado – April 21, 2021 – Gevo, Inc. (NASDAQ: GEVO) announced today that it will host a conference call on Thursday, May 13, 2021 at 4:30 p.m. EDT (2:30 p.m. MDT) to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate highlights.

To participate in the conference call, please dial 1 (833) 729-4776 (inside the U.S.) or 1 (830) 213-7701 (outside the U.S.) and reference the access code 6295166# or through the event weblink:
https://edge.media-server.com/mmc/p/ocbho96s

A replay of the call and webcast will be available two hours after the conference call ends on May 13, 2021. To access the replay, please dial 1 (855) 859-2056 (inside the U.S.) or 1 (404) 537-3406 (outside the U.S.) and reference the access code 6295166#. The archived webcast will be available in the Investor Relations section of Gevo’s website at 
www.gevo.com.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that the Argonne National Laboratory GREET model is the best available standard of scientific-based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

 

Investor and Media Contact
+1 720-647-9605
[email protected]

Release – Ayala Pharmaceuticals (AYLA) – Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent WVT078

Posted on by Admin


Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma

 

REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the dosing of the first patient in the ongoing Phase 1 clinical trial evaluating its potent investigational gamma secretase inhibitor (GSI), AL102, in combination with Novartis’ investigational anti-B-cell maturation antigen (BCMA) agent, WVT078, for the treatment of patients with relapsed and/or refractory multiple myeloma (MM).

AL102 is an oral small molecule that inhibits gamma secretase. Inhibition of gamma secretase prevents the cleavage and shedding of BCMA, which are ubiquitously expressed on MM cells. Preclinical data have demonstrated that treatment with AL102 increases expression of membrane-bound BCMA on the surface of MM cells and could enhance activity of WVT078.

“The dosing of the first patient in this Phase 1 trial marks an important milestone in our collaboration with Novartis. We view this trial, not only as a significant opportunity to explore the clinical viability of enhancing BCMA-targeting agents with GSIs such as AL102, but also as an important step forward in bringing a novel treatment option to patients with MM,” said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. “Despite numerous advances in the treatment landscape for MM, the disease remains incurable. BCMA is ubiquitously expressed on myeloma cells. Increasing BCMA expression on target cells and reducing the shedding in circulation is believed to potentially enhance therapies and increase responses. We look forward to further evaluating this potential as we bring this program into the clinic.”

The Phase 1, open-label, multicenter trial of AL102 in combination with Novartis’ WVT078 is currently enrolling patients with relapsed and/or refractory multiple myeloma who have received two or more standard of care lines of therapy including an IMID, a proteasome inhibitor, and an anti-CD38 agent. The first-in-human dose escalation trial is designed to assess the safety, tolerability and recommended dose regimen(s) of WVT078 alone and in combination with AL102. In addition, the trial will assess preliminary anti-MM response and characterize the pharmacokinetics and immunogenicity of WVT078 alone and in combination with AL102.

Under the terms of the option and license agreement established in December 2018, Novartis is responsible for the conduct and expenses of any trials of AL102 in combination with their BCMA-targeting agents, as well as potential commercialization, in multiple myeloma. Ayala retains worldwide license rights to AL102 in all other indications.

About AL102
AL102 is a potent, selective and oral gamma secretase inhibitor (GSI). AL102 is currently being developed for the treatment of desmoid tumors, as well as in combination with Novartis’ BCMA-targeting agents for the treatment of multiple myeloma (MM).

About WVT078
WVT078 is a bispecific antibody that engages both BCMA and CD3, resulting in the recruitment of cytotoxic T cells that target BCMA-positive MM cells.

About Multiple Myeloma
Multiple myeloma is a rare and aggressive blood cancer that accounts for approximately one percent of all cancers. In the U.S., there are nearly 90,000 people living with, or in remission from, multiple myeloma. Approximately, 26,850 Americans are diagnosed with multiple myeloma each year and 11,240 patient deaths are reported on an annual basis.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trial for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
[email protected]

Ayala Pharmaceuticals:
+1-857-444-0553
[email protected]

Release – Kratos Defense and Security Solutions (KTOS) – Awarded Approximately $30 Million to Support Space-Related National Security Efforts

Posted on by Admin


Kratos Awarded Approximately $30 Million to Support Space-Related National Security Efforts

 

SAN DIEGO, 
April 21, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it had received more than 
$30 million to support space-related 
U.S. national security efforts. The follow-on awards are to previous contracts, implementing advanced technologies to provide better system performance.  

“Kratos enables technological approaches and modernization that were not possible even a few years ago, but can now support this program for many years to come with the inherent flexibility to upgrade and evolve at the speed of relevance,” commented Senior Vice President  Frank Backes. “Kratos’ broad space portfolio is focused on technology-leading products and services that realize the 
DoD’s vision of data being an asset. These advanced capabilities are scalable, flexible and resilient; allowing real-time data to flow from multiple domains in support of national defense.”

Phil Carrai, President of Kratos’ Space, Training and Cybersecurity Division, said, “Space is undergoing a renaissance. Advancements in ground systems and satellite technologies are joining to form space networks that support multi-domain missions and broader data requirements. Kratos is leading the digital transformation on the ground side by introducing into space networks proven technologies from other network-centric industries. Not only does this enhance performance and affordability for the 
DoD, it opens doors for the defense industry to better integrate with and capitalize on commercial space enterprises as well.”

Due to competitive, customer-related and other considerations, no additional information will be provided.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
[email protected]

Source: Kratos Defense & Security Solutions, Inc.

Release – electroCore Inc. (ECOR) – Announces Exclusive Distribution Agreement with East Agency For Qatar

Posted on by Admin


electroCore, Inc. Announces Exclusive Distribution Agreement with East Agency For Qatar

 

ROCKAWAY, NJ, 
April 20, 2021 (GLOBE NEWSWIRE) —  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with East Agency to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) to patients suffering from primary headache disorders in 
Qatar.

“East Agency is a dedicated healthcare company focusing on high-end technologies and innovations targeting the Qatari market, and the addition of such an innovative technology in electroCore’s nVNS therapy is a matter of pride for us” said Mohammed Abdul Moqeeth, Head of the 
Medical Division of East Agency. “nVNS therapy can save patients from traumatic situations with no present solutions and it is always exciting to offer solutions rather than just products. 
East Agency is determined to honor its commitment to establish gammaCore in the region.”

“We are excited to be working with 
East Agency as we bring our nVNS therapy to the 
Middle East region initially in the State of Qatar” said Iain Strickland, electroCore’s Vice President of European Operations. “East Agency is experienced in introducing innovative medical technologies within 
Qatar and we look forward to supporting them in introducing our nVNS therapy, gammaCore Sapphire, in the region.”

The initial term of the agreement is three years, and it contains customary terms and conditions, including minimum purchase commitments.

        
About East Agency

East Agency was founded in 1997 as a sister concern of 
AlAli Holdings. The company is privately owned and has diversified business activities marking its presence in almost every sector of the medical industry.

East Agency has been providing quality healthcare services to 
Qatar in government, Public and Private sectors dealing in Dental, Medical Devices, Hospital consumables, Pharma, Derma, Lab Chemicals and Diagnostic Equipment & Reagents.

For more information, visit http://medical.eastagency.com/about-us.html

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients with:
    • An active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • A metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
    • An open wound, rash, infection, swelling, cut, sore, drug patch, or surgical scar(s) on the neck at the treatment location
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric
    • Patients (younger than 12 years)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in 
Qatar and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.


Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]